{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:54Z","timestamp":1786991214379,"version":"build-2736575974"},"reference-count":142,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.jaad.2006.06.019","type":"journal-article","created":{"date-parts":[[2006,12,25]],"date-time":"2006-12-25T07:04:45Z","timestamp":1167030285000},"page":"69-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Cutaneous sarcoidosis therapy updated"],"prefix":"10.1016","volume":"56","author":[{"given":"Christy","family":"Badgwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.06.019_bib1","first-page":"1105","article-title":"Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor","volume":"145","author":"Chensue","year":"1994","journal-title":"Am J Path"},{"key":"10.1016\/j.jaad.2006.06.019_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2796.2003.01075.x","article-title":"Treatment of sarcoidosis\u2014from a basic science point of view","volume":"253","author":"Moller","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1183\/09031936.98.12030716","article-title":"Sarcoidosis: immunopathogenetic concepts and their clinical application","volume":"12","author":"Muller-Quernheim","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaad.2006.06.019_bib4","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.4049\/jimmunol.156.12.4952","article-title":"Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis","volume":"156","author":"Moller","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib5","first-page":"174","article-title":"Involvement of T-cells and alterations in T-cell receptors in sarcoidosis","volume":"13","author":"Moller","year":"1998","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.jaad.2006.06.019_bib6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/pgmj.72.846.196","article-title":"Sarcoidosis","volume":"72","author":"Peckman","year":"1996","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2006.06.019_bib7","series-title":"Harrison's principles of internal medicine","first-page":"2017","article-title":"Sarcoidosis","author":"Crystal","year":"2005"},{"key":"10.1016\/j.jaad.2006.06.019_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2796.2003.01076.x","article-title":"Difficult treatment issues in sarcoidosis","volume":"253","author":"Baughman","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","author":"Statement on sarcoidosis","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archderm.1997.03890380087013","article-title":"Ulcerative sarcoidosis: case\u00a0report and review of the literature","volume":"133","author":"Albertini","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/pupt.2000.0243","article-title":"Molecular mechanisms of glucocorticosteroid actions","volume":"13","author":"Adcock","year":"2000","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaad.2006.06.019_bib12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.278.5339.866","article-title":"IkB kinase-beta: NF-kB activation and complex formation with IkB kinase-alpha and NIK","volume":"278","author":"Woronicz","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jaad.2006.06.019_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2249.1997.d01-979.x","article-title":"Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung","volume":"108","author":"Milburn","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2340\/00015555726971","article-title":"Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing","volume":"72","author":"Volden","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.06.019_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archderm.1995.01690170121026","article-title":"Lupus pernio: successful treatment with a potent topical corticosteroid","volume":"131","author":"Khatri","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib16","first-page":"418","article-title":"Cutaneous sarcoidosis: diagnosis and treatment","volume":"20","author":"Russo","year":"1994","journal-title":"Compr Ther"},{"issue":"suppl 12","key":"10.1016\/j.jaad.2006.06.019_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2133.1976.tb02269.x","article-title":"The place of intralesional steroid therapy in dermatology","volume":"94","author":"Verbov","year":"1976","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1067\/mjd.2001.114596","article-title":"Sarcoidosis","volume":"44","author":"English","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0738-081X(86)90036-2","article-title":"Cutaneous sarcoidosis: prognosis and treatment","volume":"4","author":"Veien","year":"1986","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib20","series-title":"Lippincott's illustrated reviews: pharmacology","year":"1997"},{"key":"10.1016\/j.jaad.2006.06.019_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0002-9343(52)90208-8","article-title":"Effects of cortisone in sarcoidosis. A study of thirteen patients","volume":"12","author":"Siltzbach","year":"1952","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0272-5231(05)70423-8","article-title":"Steroid-sparing alternative treatments for sarcoidosis","volume":"18","author":"Baughman","year":"1997","journal-title":"Clin Chest Med"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2006.06.019_bib23","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1177\/0961203393002001031","article-title":"Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation","volume":"2","author":"Fox","year":"1993","journal-title":"Lupus"},{"issue":"suppl 425","key":"10.1016\/j.jaad.2006.06.019_bib24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.0954-6820.1964.tb05780.x","article-title":"Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis","volume":"176","author":"Siltzbach","year":"1964","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jaad.2006.06.019_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9343(61)90213-3","article-title":"The treatment of sarcoidosis with chloroquine","volume":"30","author":"Morse","year":"1961","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib26","first-page":"257","article-title":"Chloroquine in the treatment of sarcoidosis. A report from the research committee of\u00a0the British Tuberculosis Association","volume":"48","author":"British Tuberculosis Association","year":"1967","journal-title":"Tubercle"},{"key":"10.1016\/j.jaad.2006.06.019_bib27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/archderm.1991.01680060108015","article-title":"Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature","volume":"127","author":"Zic","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0190-9622(90)70246-E","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","author":"Jones","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1365-4362.1996.tb03710.x","article-title":"Intralesional chloroquine for the treatment of cutaneous sarcoidosis","volume":"35","author":"Liedtka","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM196609292751303","article-title":"Delayed onset of chloroquine retinopathy","volume":"275","author":"Burns","year":"1966","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib31","first-page":"191","article-title":"Updated ophthalmological screening and follow-up management for long-term antimalarial treatment","volume":"27","author":"Rigaudiere","year":"2004","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jaad.2006.06.019_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0190-9622(82)70002-7","article-title":"Antimalarials and ophthalmologic safety","volume":"6","author":"Olansky","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000246421","article-title":"Chloroquine: consideration of maximum daily dose (3.5 mg\/kg ideal body weight) prevents retinopathy","volume":"192","author":"Ochsendorf","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.06.019_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2133.1999.02600.x","article-title":"Ocular toxicity and hydroxychloroquine: guidelines for screening","volume":"140","author":"Jones","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard.56.3.188","article-title":"Hydroxychloroquine and visual screening in a\u00a0rheumatology outpatient clinic","volume":"56","author":"Grierson","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib36","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0161-6420(03)00409-3","article-title":"The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal","volume":"110","author":"Mavrikakis","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2006.06.019_bib37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.jaad.2006.06.019_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00000441-199003000-00002","article-title":"The use of low dose methotrexate in refractory sarcoidosis","volume":"299","author":"Lower","year":"1990","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaad.2006.06.019_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0190-9622(91)70071-9","article-title":"Weekly low-dose methotrexate therapy for cutaneous sarcoidosis","volume":"24","author":"Webster","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib40","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib41","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/thx.54.8.742","article-title":"A clinical approach to the use of methotrexate for sarcoidosis","volume":"54","author":"Baughman","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.jaad.2006.06.019_bib42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0889-857X(05)70369-0","article-title":"The use of folates concomitantly with low-dose pulse methotrexate","volume":"23","author":"Shiroky","year":"1997","journal-title":"Rheum Dis Clin"},{"key":"10.1016\/j.jaad.2006.06.019_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/ard.55.5.273","article-title":"Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists","volume":"55","author":"Hassan","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09546630410023584","article-title":"Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach","volume":"15","author":"Mosam","year":"2004","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2006.06.019_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00063030-200317060-00005","article-title":"Tumor necrosis factor in sarcoidosis and its potential for targeted therapy","volume":"17","author":"Baughman","year":"2003","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaad.2006.06.019_bib46","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1164\/ajrccm.159.2.9804085","article-title":"Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages","volume":"159","author":"Marques","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib47","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1378\/chest.124.4.1526","article-title":"Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline. Comparison with dexamethasone","volume":"124","author":"Tong","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2006.06.019_bib48","first-page":"107","article-title":"Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis","volume":"23","author":"Korber","year":"1995","journal-title":"Immun Infekt"},{"key":"10.1016\/j.jaad.2006.06.019_bib49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2567.1997.00246.x","article-title":"Inhibition of human interleukin-12 production by pentoxifylline","volume":"91","author":"Moller","year":"1997","journal-title":"Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib50","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1164\/ajrccm.155.5.9154873","article-title":"Pentoxifylline in treatment of sarcoidosis","volume":"155","author":"Zabel","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1378\/chest.126.1.321","article-title":"Anti-inflammatory effect of pentoxifylline","volume":"126","author":"Inoue","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2006.06.019_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.autrev.2003.10.001","article-title":"Sarcoidosis succumbs to antibiotics\u2014implications for autoimmune disease","volume":"3","author":"Marshall","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2006.06.019_bib53","first-page":"2","article-title":"Antibiotics in sarcoidosis\u2014reflections of the first year","volume":"1","author":"Marshall","year":"2003","journal-title":"J Indep Med Res"},{"key":"10.1016\/j.jaad.2006.06.019_bib54","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/archderm.1994.01690060078008","article-title":"Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C","volume":"130","author":"Webster","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib55","doi-asserted-by":"crossref","first-page":"F760","DOI":"10.1152\/ajprenal.00050.2004","article-title":"Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury","volume":"287","author":"Kelly","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jaad.2006.06.019_bib56","first-page":"443","article-title":"Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues","volume":"35","author":"Thong","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib57","first-page":"728","article-title":"Effect of tetracycline treatment on immunologic responses in mice","volume":"39","author":"Thong","year":"1980","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2003.03014.x","article-title":"Subantimicrobial dose doxycycline for acne and rosacea","volume":"2","author":"Bikowski","year":"2003","journal-title":"Skinmed"},{"key":"10.1016\/j.jaad.2006.06.019_bib59","first-page":"69","article-title":"The\u00a0use of tetracyclines for the treatment of sarcoidosis","volume":"137","author":"Bachelez","year":"2001","journal-title":"Arch\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000250171","article-title":"Granulomatous rosacea treated with tetracycline","volume":"163","author":"Veien","year":"1981","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2006.06.019_bib61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2340\/0001555565270272","article-title":"Sarcoid-like granulomatous periocular dermatitis treated with tetracycline","volume":"65","author":"Falk","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.06.019_bib62","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI115438","article-title":"Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats","volume":"88","author":"Massacesi","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2006.06.019_bib63","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/1523-1747.ep12284027","article-title":"Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro","volume":"93","author":"Dupuy","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib64","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.1983.01650360049012","article-title":"Treatment of cutaneous sarcoidosis with isotretinoin","volume":"119","author":"Waldinger","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib65","first-page":"1089","article-title":"Annular cutaneous sarcoidosis of the forehead: treatment with isotretinoin","volume":"113","author":"Vaillant","year":"1986","journal-title":"Ann Derm Venereol"},{"key":"10.1016\/j.jaad.2006.06.019_bib66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/000155598442782","article-title":"Cutaneous sarcoidosis: complete remission after oral isotretinoin therapy","volume":"78","author":"Georgiou","year":"1998","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.06.019_bib67","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2230.2005.01729.x","article-title":"Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore","volume":"30","author":"Chong","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib68","unstructured":"Goodfield M, Cox N, Dudley A, Mc Millian C, Millard L, Simpson N. Clinical guidelines. Advice on the safe introduction and continued use of isotretinoin in acne. Available at:\u00a0http:\/\/www.bad.org.uk\/healthcare\/guidelines\/acne.asp. Accessed June 29, 2005."},{"key":"10.1016\/j.jaad.2006.06.019_bib69","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib70","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/rheumatology\/keg156","article-title":"Successful treatment of sarcoidosis with leflunomide","volume":"42","author":"Majithia","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2006.06.019_bib71","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoid Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib72","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007890-199907150-00020","article-title":"In\u00a0vivo activity of leflunomide. Pharmacokinetic analyses and mechanism of immunosuppression","volume":"68","author":"Chong","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2006.06.019_bib73","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000074120","article-title":"Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide","volume":"207","author":"Fischer","year":"2003","journal-title":"Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib74","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1346-8138.2003.tb00490.x","article-title":"Exfoliative dermatitis induced by leflunomide therapy","volume":"30","author":"Bandyopadhyay","year":"2003","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib75","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","article-title":"The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures","volume":"99","author":"McHugh","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib76","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00063030-200115100-00005","article-title":"Theoretical basis for the activity of thalidomide","volume":"15","author":"Meierhofer","year":"2001","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaad.2006.06.019_bib77","unstructured":"Perri AJ III, Hsu S. A review of thalidomide's history and current dermatologic applications. Dermatology Online Journal. Available at: http:\/\/dermatology.cdlib.org. Accessed April 2, 2006."},{"key":"10.1016\/j.jaad.2006.06.019_bib78","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0954-6111(97)90134-7","article-title":"Thalidomide reduces tumor necrosis factor-alpha production by human alveolar macrophages","volume":"91","author":"Tavares","year":"1997","journal-title":"Respir Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib80","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib81","first-page":"963","article-title":"Cutaneous sarcoidosis. Treatment with thalidomide","volume":"12","author":"Barriere","year":"1983","journal-title":"Presse Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib82","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0190-9622(95)91549-4","article-title":"Treatment of cutaneous and pulmonary sarcoidosis with thalidomide","volume":"32","author":"Carlesimo","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib83","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/archderm.134.8.1045","article-title":"Cutaneous sarcoidosis successfully treated with low dose of thalidomide","volume":"134","author":"Rousseau","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib84","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0248-8663(97)80724-2","article-title":"Effectiveness of thalidomide treatment during cutaneous sarcoidosis","volume":"19","author":"Grasland","year":"1998","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jaad.2006.06.019_bib85","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0190-9622(98)70360-3","article-title":"Disfiguring cutaneous manifestation of\u00a0sarcoidosis treated with thalidomide: a case report","volume":"39","author":"Lee","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1378\/chest.122.1.227","article-title":"Thalidomide for chronic sarcoidosis","volume":"122","author":"Baughman","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2006.06.019_bib87","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/clim.2001.5173","article-title":"Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement","volume":"102","author":"Oliver","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaad.2003.07.006","article-title":"Treatment of cutaneous sarcoidosis with thalidomide","volume":"50","author":"Nguyen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib89","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib90","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharm Exp Ther"},{"key":"10.1016\/j.jaad.2006.06.019_bib91","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman","year":"2001","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib92","first-page":"413","article-title":"The use of infliximab in cutaneous sarcoidosis","volume":"2","author":"Meyerle","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib93","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1067\/mjd.2003.228","article-title":"Progressive cutaneous sarcoidosis responding to\u00a0anti-tumor necrosis factor-alpha therapy","volume":"48","author":"Mallbris","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib94","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1378\/chest.124.5.2028","article-title":"Refractory sarcoidosis responding to infliximab","volume":"124","author":"Roberts","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2006.06.019_bib95","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2133.2004.05769.x","article-title":"Infliximab therapy for sarcoidosis (lupus pernio)","volume":"150","author":"Haley","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib96","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archneur.60.3.426","article-title":"The pathogenesis and treatment of optic disc swelling in neurosarcoidosis. A unique therapeutic response to infliximab","volume":"60","author":"Katz","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jaad.2006.06.019_bib97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","article-title":"Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy","volume":"135","author":"Yee","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib98","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1002\/art.11357","article-title":"Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis","volume":"48","author":"Ulbricht","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2006.06.019_bib99","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2002.004226","article-title":"Tumor necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients","volume":"63","author":"Pritchard","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib100","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2006.06.019_bib101","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor-necrosis factor (alpha)-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib102","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00003495-199856030-00003","article-title":"Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection","volume":"56","author":"Jackson","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2006.06.019_bib104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1378\/chest.78.1.36","article-title":"Chlorambucil in sarcoidosis","volume":"78","author":"Kataria","year":"1980","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2006.06.019_bib105","first-page":"35","article-title":"Chlorambucil treatment of sarcoidosis","volume":"8","author":"Isreal","year":"1991","journal-title":"Sarcoidosis"},{"key":"10.1016\/j.jaad.2006.06.019_bib106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/014107688407700218","article-title":"Fatal herpes simplex infection during chlorambucil therapy for sarcoidosis","volume":"77","author":"Sahgal","year":"1984","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib107","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1567-5769(02)00088-7","article-title":"Effects and mechanisms of melatonin on inflammatory and immune responses of adjuvant arthritis rat","volume":"2","author":"Chen","year":"2002","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2006.06.019_bib108","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1600-079X.1994.tb00128.x","article-title":"Inhibitory effect of melatonin on production of IFN-gamma or TNF-alpha in peripheral blood mononuclear cells of some blood donors","volume":"17","author":"Di Stefano","year":"1994","journal-title":"J Pineal Res"},{"key":"10.1016\/j.jaad.2006.06.019_bib109","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00916958","article-title":"Immunomodulation by indoleamines: serotonin and melatonin action on DNA and interferon-gamma synthesis by human peripheral blood mononuclear cells","volume":"8","author":"Arzt","year":"1988","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s007020170061","article-title":"Pineal indoles stimulate the gene expression of immunomodulating cytokines","volume":"108","author":"Liu","year":"2001","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jaad.2006.06.019_bib111","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0140-6736(95)92935-5","article-title":"Melatonin for treatment of chronic refractory sarcoidosis","volume":"346","author":"Cagnoni","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.06.019_bib112","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.lfs.2004.03.023","article-title":"A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin","volume":"75","author":"Mulchahey","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.jaad.2006.06.019_bib113","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/ajrccm\/138.5.1242","article-title":"Evaluation of the in vitro and in vivo effects of cyclosporine on the T-lymphocyte alveolitis of active pulmonary sarcoidosis","volume":"138","author":"Martinet","year":"1988","journal-title":"Am Rev Repir Dis"},{"key":"10.1016\/j.jaad.2006.06.019_bib114","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jaad.2006.06.019_bib115","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(84)91411-9","article-title":"Cyclosporin for pulmonary sarcoidosis","volume":"1","author":"Rebuck","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.06.019_bib116","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1183\/09031936.94.07122255","article-title":"Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning","volume":"7","author":"O'Callaghan","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaad.2006.06.019_bib117","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/S0140-6736(87)92230-6","article-title":"Cyclosporin in pulmonary sarcoidosis","volume":"1","author":"Rebuck","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.06.019_bib118","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2133.1998.02298.x","article-title":"Subcutaneous sarcoidosis worsened by cyclosporin treatment for pyoderma gangrenosum","volume":"138","author":"Losada","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib119","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/ajrccm.156.5.9506031","article-title":"Treatment of progressive pulmonary sarcoidosis with cyclosporin A","volume":"156","author":"Wyser","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib120","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib121","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2004.05768.x","article-title":"Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors","volume":"150","author":"Mizuno","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib122","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2249.2001.01655.x","article-title":"Heightened ability of monocytes from sarcoidosis to form multi-nucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells","volume":"126","author":"Mizuno","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2006.06.019_bib123","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM197602192940819","article-title":"Allopurinol for sarcoid?","volume":"294","author":"Rosef","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib124","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archderm.1980.01640270033006","article-title":"Sarcoidosis responding to allopurinol","volume":"116","author":"Pollock","year":"1980","journal-title":"Arch Dermatol"},{"issue":"suppl 26","key":"10.1016\/j.jaad.2006.06.019_bib125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2133.1984.tb05238.x","article-title":"Sarcoidosis: initial results on six patients treated with allopurinol","volume":"111","author":"Samuel","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2133.1996.tb01168.x","article-title":"Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis","volume":"135","author":"Brechtel","year":"1996","journal-title":"Br\u00a0J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib127","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1046\/j.1365-2133.2000.03500.x","article-title":"A case of cutaneous acral sarcoidosis with response to allopurinol","volume":"142","author":"Antony","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib128","first-page":"1184","article-title":"Sarcoidosis in a child treated successfully with allopurinol","volume":"140","author":"El-Euch","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib129","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s001050050730","article-title":"Allopurinol in treatment of cutaneous sarcoidosis","volume":"49","author":"Pfau","year":"1998","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2006.06.019_bib130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/09546630510027886","article-title":"Low-dose allopurinol in the treatment of cutaneous sarcoidosis: response in four of seven patients","volume":"16","author":"Breghoej","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2006.06.019_bib131","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archderm.135.12.1560","article-title":"Treatment of subcutaneous sarcoidosis with allopurinol","volume":"135","author":"Voelter-Mahlknecht","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib132","first-page":"262","article-title":"Treatment of laryngeal sarcoidosis with CO2 laser and mitomycin-C","volume":"130","author":"James","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaad.2006.06.019_bib133","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/lsm.10059","article-title":"Scar sarcoidosis\u2014treatment with the Q-switched ruby laser","volume":"30","author":"Grema","year":"2002","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib134","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2230.2005.01960.x","article-title":"Laser remodeling of nodular nasal lupus pernio","volume":"31","author":"O'Donoghue","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib135","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/lsm.1900120515","article-title":"Treatment of lupus pernio with the flashlamp pulsed dye laser","volume":"12","author":"Goodman","year":"1992","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2006.06.019_bib136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14628839950517101","article-title":"The successful treatment of lupus pernio with the flashlamp pulsed dye laser","volume":"1","author":"Cliff","year":"1999","journal-title":"J Cutan Laser Ther"},{"key":"10.1016\/j.jaad.2006.06.019_bib137","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0196-0709(96)90092-7","article-title":"CO2 laser excision of lupus pernio of the face","volume":"17","author":"Stack","year":"1996","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.jaad.2006.06.019_bib138","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/147641702321136255","article-title":"CO2 laser vaporization for disfiguring lupus pernio","volume":"4","author":"Young","year":"2002","journal-title":"J Cosmet Laser Ther"},{"key":"10.1016\/j.jaad.2006.06.019_bib139","first-page":"507","article-title":"Generalized ulcerative sarcoidosis induced by therapy with the flashlamp-pumped pulsed dye laser","volume":"137","author":"Green","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.019_bib140","first-page":"53","article-title":"Cutaneous sarcoidosis at sites of previous laser surgery","volume":"73","author":"Kormeili","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2006.06.019_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00016348409156383","article-title":"Drug use during pregnancy and breast-feeding. A classification system for drug information","volume":"126","author":"Berglund","year":"1984","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"10.1016\/j.jaad.2006.06.019_bib142","unstructured":"Brent R. Experts' answers. Health Physics Society. Available at: http:\/\/www.hps.org. Accessed January 19, 2006."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206018019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206018019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:05:45Z","timestamp":1759269945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206018019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0190962206018019"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.06.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous sarcoidosis therapy updated","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}